JGC
TRAX

J. Goldman & Co’s First Tracks Biotherapeutics TRAX Stock Holding History

J. Goldman & Co’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$943K Buy
+46,847
New +$876K 0.02% 471

Other funds holding TRAX

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

J. Goldman & Co's TRAX Position: Q2 2026 in Review

J. Goldman & Co opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 46,847 shares worth $943K. The stake represents 0.02% of the portfolio and ranks #471 among its holdings.

150 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • J. Goldman & Co held 46,847 shares of First Tracks Biotherapeutics worth $943K as of Q2 2026.
  • First Tracks Biotherapeutics was a new J. Goldman & Co position in Q2 2026.
  • First Tracks Biotherapeutics made up 0.02% of J. Goldman & Co's portfolio in Q2 2026, its #471 holding.
  • 150 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.